PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 902 participants.
Also called NCT02171065
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose basic science
- Phase
- Not applicable
- Enrolled
- 902 participants
- Registry
-
NCT02171065
-
- Other papers using this trial's data
- Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque
- Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI: Insights From the PROSPECT II Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02171065. Randomized; no masking; primary purpose basic science. Start 2014-06 (actual); primary completion 2020-05 (actual). Results posted on 2021-08-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
- Acronym
- P2
- Condition
- Acute Coronary Syndrome (ACS)
- Intervention (Device)
- sham
- Intervention (Device)
- ABSORB BVS
- Lead sponsor
- Uppsala University
- Collaborator
- Abbott Medical Devices
- Collaborator
- Infraredx
- Collaborator
- The Medicines Company
Record details
- Record id
cardio:ct-nct02171065- Content hash
7322fe93f66cb83ff669dcfbb7fccc06ee0c2c381aeda48e41436b40e6b1cca0